AU2012229104B2 - Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen - Google Patents

Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen Download PDF

Info

Publication number
AU2012229104B2
AU2012229104B2 AU2012229104A AU2012229104A AU2012229104B2 AU 2012229104 B2 AU2012229104 B2 AU 2012229104B2 AU 2012229104 A AU2012229104 A AU 2012229104A AU 2012229104 A AU2012229104 A AU 2012229104A AU 2012229104 B2 AU2012229104 B2 AU 2012229104B2
Authority
AU
Australia
Prior art keywords
interferon
week
patient
intramuscular administration
titration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012229104A
Other languages
English (en)
Other versions
AU2012229104A1 (en
Inventor
Aaron Deykin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of AU2012229104A1 publication Critical patent/AU2012229104A1/en
Assigned to BIOGEN INC. reassignment BIOGEN INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: BIOGEN IDEC INC.
Application granted granted Critical
Publication of AU2012229104B2 publication Critical patent/AU2012229104B2/en
Assigned to BIOGEN MA INC. reassignment BIOGEN MA INC. Request for Assignment Assignors: BIOGEN INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
AU2012229104A 2011-03-15 2012-03-15 Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen Active AU2012229104B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161452807P 2011-03-15 2011-03-15
US61/452,807 2011-03-15
US201161476930P 2011-04-19 2011-04-19
US61/476,930 2011-04-19
PCT/US2012/029201 WO2012125809A1 (en) 2011-03-15 2012-03-15 Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen

Publications (2)

Publication Number Publication Date
AU2012229104A1 AU2012229104A1 (en) 2013-10-03
AU2012229104B2 true AU2012229104B2 (en) 2017-03-16

Family

ID=46045072

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012229104A Active AU2012229104B2 (en) 2011-03-15 2012-03-15 Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen

Country Status (25)

Country Link
US (6) US9198955B2 (enExample)
EP (1) EP2686002B1 (enExample)
JP (2) JP6279905B2 (enExample)
KR (1) KR102050339B1 (enExample)
CN (1) CN103702680A (enExample)
AU (1) AU2012229104B2 (enExample)
BR (1) BR112013023609A8 (enExample)
CA (1) CA2846786C (enExample)
CY (1) CY1120176T1 (enExample)
DK (1) DK2686002T3 (enExample)
EA (1) EA028448B1 (enExample)
ES (1) ES2666850T3 (enExample)
HR (1) HRP20180621T1 (enExample)
HU (1) HUE036931T2 (enExample)
IL (1) IL228425A (enExample)
LT (1) LT2686002T (enExample)
MX (1) MX359947B (enExample)
PL (1) PL2686002T3 (enExample)
PT (1) PT2686002T (enExample)
RS (1) RS57175B1 (enExample)
SG (1) SG193446A1 (enExample)
SI (1) SI2686002T1 (enExample)
SM (1) SMT201800221T1 (enExample)
WO (1) WO2012125809A1 (enExample)
ZA (1) ZA201306933B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012125809A1 (en) * 2011-03-15 2012-09-20 Biogen Idec Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
HK1226092A1 (zh) * 2014-01-09 2017-09-22 Kyushu University, National University Corporation 制备小胶质细胞的方法
WO2018056584A1 (ko) 2016-09-21 2018-03-29 삼성전자 주식회사 피부 상태 측정 방법 및 이를 위한 전자 장치
CN116391233A (zh) * 2020-09-30 2023-07-04 皇家飞利浦有限公司 用于执行剂量滴定的方法和系统

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
DE3273787D1 (en) 1981-02-04 1986-11-20 Japan Found Cancer Human interferon-beta gene
US4695543A (en) 1982-03-23 1987-09-22 Bristol-Myers Company Alpha Interferon GX-1
CA1302320C (en) 1984-06-11 1992-06-02 Hideo Niwa Expression of human cromosomal interferon-_ in animal cells
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
FI90990C (fi) 1984-12-18 1994-04-25 Boehringer Ingelheim Int Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
EP0205404B1 (en) 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
US5641656A (en) 1993-10-22 1997-06-24 University Of Connecticut Nucleic acids encoding avian interferon (IFN) proteins and recombinant methods using them
TR199901968T2 (xx) * 1996-12-24 1999-12-21 Biogen, Inc. Sabit s�v� interferon form�lleri.
JP2001104482A (ja) * 1999-10-07 2001-04-17 Terumo Corp ２室型プレフィルドシリンジ
ES2712469T3 (es) * 2003-01-30 2019-05-13 Becton Dickinson Co Soporte con escudo de seguridad para un dispositivo de administración de fármaco
BRPI0510526A (pt) * 2004-06-01 2007-10-30 Ares Trading Sa formulações lìquidas estabilizadas de interferon
US20060089593A1 (en) * 2004-10-26 2006-04-27 Sergio Landau Needle-free injection device for individual users
EP1923085A1 (en) * 2006-11-17 2008-05-21 Sanofi-Aventis Deutschland GmbH Dosing and drive mechanism for drug delivery device
JP2010513309A (ja) * 2006-12-18 2010-04-30 アルタス ファーマシューティカルズ インコーポレイテッド ヒト成長ホルモン製剤
US9044378B2 (en) * 2007-05-31 2015-06-02 Safety Syringes, Inc. Anti-needle stick safety device or system for use with drugs requiring reconstitution
JP5549048B2 (ja) * 2007-08-16 2014-07-16 味の素株式会社 薬剤バイアルとプレフィルドシリンジの接続構造
WO2010148337A1 (en) * 2009-06-18 2010-12-23 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
WO2012125809A1 (en) * 2011-03-15 2012-09-20 Biogen Idec Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"AVONEX ® (Interferon beta-1a) IM Injection". 2006. Retrieved from the internet on 28/11/2016: URL: www.accessdata.fda.gov/drugsatfda_docs/label/2007/103628s5115lbl.pdf *
Anon: 'Medication guide appendix: Instructions for preparing and giving a dose with an Avonex prefilled syringe'. 2010. Internet: URL: http//www.avonex.com/pdfs/guides/Liquid_appendix_161023.pdf *
FROHMAN, E. et al. 'Disease-modifying therapy in multiple sclerosis: strategies for optimizing management'. The Neurologist. 2002. 8: 227-236 *
PHILLIPS, J.T. et al. Clinical Therapeutics. 2004. 26(4): 511-521 *

Also Published As

Publication number Publication date
CY1120176T1 (el) 2018-12-12
MX2013010507A (es) 2014-04-30
US20220280610A1 (en) 2022-09-08
HUE036931T2 (hu) 2018-08-28
IL228425A (en) 2017-08-31
CN103702680A (zh) 2014-04-02
EP2686002B1 (en) 2018-01-24
SMT201800221T1 (it) 2018-07-17
RS57175B1 (sr) 2018-07-31
US20200046804A1 (en) 2020-02-13
KR102050339B1 (ko) 2019-11-29
SI2686002T1 (en) 2018-06-29
MX359947B (es) 2018-10-17
EA028448B1 (ru) 2017-11-30
WO2012125809A1 (en) 2012-09-20
NZ712273A (en) 2016-09-30
US9198955B2 (en) 2015-12-01
KR20140038383A (ko) 2014-03-28
BR112013023609A2 (pt) 2016-12-06
ZA201306933B (en) 2016-07-27
ES2666850T3 (es) 2018-05-08
US20250276042A1 (en) 2025-09-04
PT2686002T (pt) 2018-04-23
US10500254B2 (en) 2019-12-10
JP2014508174A (ja) 2014-04-03
JP6279905B2 (ja) 2018-02-14
US20120237479A1 (en) 2012-09-20
AU2012229104A1 (en) 2013-10-03
LT2686002T (lt) 2018-05-10
EA201301024A1 (ru) 2014-03-31
CA2846786C (en) 2022-05-17
EP2686002A1 (en) 2014-01-22
JP2018030847A (ja) 2018-03-01
BR112013023609A8 (pt) 2018-04-03
CA2846786A1 (en) 2012-09-20
HRP20180621T1 (hr) 2018-07-27
DK2686002T3 (en) 2018-04-30
PL2686002T3 (pl) 2018-10-31
SG193446A1 (en) 2013-10-30
NZ616536A (en) 2015-10-30
US20170360890A1 (en) 2017-12-21
IL228425A0 (en) 2013-12-31
US20160101157A1 (en) 2016-04-14
JP6522069B2 (ja) 2019-05-29

Similar Documents

Publication Publication Date Title
US20250276042A1 (en) Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
EP2533634B1 (en) Neuroprotection in demyelinating diseases
CN102458476A (zh) 用于治疗多发性硬化症的组合物及方法
AU776181B2 (en) Combined treatment of multiple sclerosis
Goodin Interferon-β therapy in multiple sclerosis: evidence for a clinically relevant dose response
HK1192473A (en) Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
HK1192473B (en) Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
NZ712273B2 (en) Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
NZ616536B2 (en) Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
EP1471974B1 (en) Tumor necrosis factor combined with interferon in demyelinating diseases
Johnson Role of interferons in demyelinating disease
HK1179116B (en) Neuroprotection in demyelinating diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: BIOGEN MA INC.

Free format text: FORMER OWNER(S): BIOGEN INC.